Lineage Cell Therapeutics
LCTX
LCTX
117 hedge funds and large institutions have $125M invested in Lineage Cell Therapeutics in 2017 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 40 increasing their positions, 18 reducing their positions, and 7 closing their positions.
Holders
117
Holders Change
+15
Holders Change %
+14.71%
% of All Funds
2.66%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
23
Increased
40
Reduced
18
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
BC
1
Broadwood Capital
New York
|
$64.4M |
| 2 |
2
Axa
Paris,
France
|
$4.94M |
| 3 |
3
Renaissance Technologies
New York
|
$2.58M |
| 4 |
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
$2.2M |
| 5 |
AG
5
Artal Group
Luxembourg
|
$3.35M |
